<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103114</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00051186</org_study_id>
    <nct_id>NCT02103114</nct_id>
  </id_info>
  <brief_title>Anti-thrombin III (ATIII) vs Placebo in Children (&lt;7mo) Undergoing Open Congenital Cardiac Surgery</brief_title>
  <official_title>Double Blind Randomized Placebo-controlled Study in Children (&lt;6mo) Comparing the Effects of Anti-thrombin III (ATIII) or Placebo on the Coagulation System in Infants With Known Low ATIII Levels Undergoing Open Congenital Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Biologicals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the administration of ATIII during the
      intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB)
      and an attenuation of the activation of the coagulation cascade, as represented by a decrease
      in fibrin degradation products. The investigators believe this benefit would extend into the
      post-operative period resulting in a decreased incidence of thrombosis generation, as
      represented by a decrease in fibrin degradation products in the ICU period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If Preoperative ATIII functional assay level is less than 70% patients would be enrolled and
      randomized to either Placebo (normal saline) or ATIII.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in ICU)</measure>
    <time_frame>Time 5 (on arrival in ICU)</time_frame>
    <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at Time 5 (on arrival in ICU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the Mean and SD of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Times 5-Time 7 (ICU Arrival to Post Operative Day 4)</measure>
    <time_frame>ICU arrival (Time 5) to Time 7 (Post-operative Day 4)</time_frame>
    <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at times 5-Time 7 (ICU arrival to Post Operative Day 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the Mean the ATIII (Functional Assay) of the Control and ATIII Groups at T1, T2, T3, T5, T6 and T7</measure>
    <time_frame>T1, T2, T3, T5, T6 and T7</time_frame>
    <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean of the ATIII (functional assay) of the control and ATIII groups at T1, T2, T3, T5, T6 and T7 (Baseline, 30 min after study drug, 30 min on CPB, Arrival in ICU, POD 2, and POD 4). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the Median of the ATIII (Functional Assay) of the Control and ATIII Groups at T4</measure>
    <time_frame>T4 (just prior to coming off of CPB)</time_frame>
    <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the ATIII (functional assay) of the control and ATIII groups at T4 (just prior to coming off of CPB). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the Median of the D Dimer of the Control and ATIII Groups at T1, T5, T6 and T7</measure>
    <time_frame>T1, T5, T6 and T7</time_frame>
    <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the D dimer of the control and ATIII groups at T1 (Baseline), T5 (Arrival in Intensive Care Unit), T6 (Post-Operative Day 2) and T7 (Post-Operative Day 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Heparin at the ICU Arrival Time Point Represented by a Decreased Anti Factor Xa Level.</measure>
    <time_frame>T5 (Intensive Care Unit Arrival)</time_frame>
    <description>Evidence of a decreased amount of residual heparin at the Intensive Care Unit arrival time point (T5) represented by a decreased anti factor Xa level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Decreased Inflammation Represented by a Decrease in Inflammatory Markers in the ATIII Group</measure>
    <time_frame>Baseline (T1) to Post-Operative Day 4 (T7)</time_frame>
    <description>Evidence of decreased inflammation represented by a decrease in inflammatory markers in the ATIII group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Heparin While on Cardiopulmonary Bypass</measure>
    <time_frame>T1 (Baseline) to T5 (Arrival in ICU)</time_frame>
    <description>Total dose of Heparin while on Cardiopulmonary Bypass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protamine Dose Determined by Hemostasis Management System Machine (mg/kg)</measure>
    <time_frame>T1 (Baseline) to T5 (Arrival in ICU)</time_frame>
    <description>Protamine dose determined by Hemostasis Management system machine (mg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Blood Products While on CPB</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
    <description>Total volume of blood products exposed intraoperatively including the pump prime (ml/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Protamine Administration to Skin Dressing</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
    <description>Time from protamine administration to skin dressing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Fresh Frozen Plasma Given Prior to CPB</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
    <description>Total volume of Fresh Frozen Plasma given prior to CPB, including the pump prime (ml/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</measure>
    <time_frame>Baseline (Intraoperatively)</time_frame>
    <description>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Postoperative Blood Loss</measure>
    <time_frame>From 10min post protamine administration to 24 hour post protamine administration</time_frame>
    <description>Volume of postoperative blood loss from 10min post protamine administration to 24 hour post protamine administration- (ml/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest Tube Output (Protamine Time Plus 24 Hours) in Milliliters</measure>
    <time_frame>protamine time plus 24 hours</time_frame>
    <description>Chest Tube output (protamine time plus 24 hours) in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Total Blood Product Units Transfused by Type 24-hours Post-operatively by Group</measure>
    <time_frame>24 Hours Post-Operatively</time_frame>
    <description>Number of packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Total Blood Product Units Transfused 24-hours Post-operatively by Group</measure>
    <time_frame>24 Hours Post-Operatively</time_frame>
    <description>Number of total blood product units (including packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units) transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Recombinant Factor 7a (VIIa) Used Intraoperatively</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Total Dose of rescue recombinant factor 7a (VIIa) used intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Post Operative Ventilation in Days</measure>
    <time_frame>ICU arrival (Time 5) to Time 7 (Post-Operative Day 4)</time_frame>
    <description>Length of post operative ventilation in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Extracorporeal Membrane Oxygenation (ECMO) Support Within 24 Hours Postoperatively</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the incidence of extracorporeal membrane oxygenation (ECMO) support within 24 hours postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Mediastinal Exploration Within 24 Hours Postoperatively</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the incidence of mediastinal exploration within 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (Number) of Thrombotic Events Documented</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of thrombotic events documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Onset Renal Failure, Defined by Stage 3 of the AKIN Criteria</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the incidence of new onset renal failure, defined by stage 3 of the Acute Kidney Injury Network (AKIN) criteria.
Serum creatinine increase ≥26.5 μmol/l (≥0.3 mg/dl) or increase to 1.5-2.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 6 hours
Serum creatinine increase &gt;2.0-3.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 12 hours
Serum creatinine increase &gt;3.0-fold from baseline or serum creatinine ≥354 μmol/l (≥4.0 mg/dl) with an acute increase of at least 44 μmol/l (0.5 mg/dl) or need for Renal replacement therapy (RRT), urine output &lt;0.3 ml/kg/h for 24 h or anuria for 12 hours or need for RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (Number) of Newly Diagnosed Intracranial Hemorrhage</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of newly diagnosed intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Delayed Sternal Closure Measured in Days</measure>
    <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
    <description>Study the safety profile of dosing the ATIII by monitoring the length of time to delayed sternal closure measured in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>ATIII Deficiency</condition>
  <arm_group>
    <arm_group_label>Anti-thrombin III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thrombin III</intervention_name>
    <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
expressed as a % normal level based on functional ATIII assay</description>
    <arm_group_label>Anti-thrombin III</arm_group_label>
    <other_name>Thrombate III</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients less than 7 months of age going for cardiac surgery that will require
             cardiopulmonary bypass (CPB) with a documented ATIII level below 70%

        Exclusion Criteria:

          -  Less than 2.5kg

          -  Known or suspected hereditary ATIII deficiency (family history of venous thrombosis
             with decreased plasma levels of ATIII and no other potential causes of acquired
             decreased ATIII)

          -  On Ecmo (extracorporeal membrane oxygenation ) at time of surgery

          -  Known history of thrombosis

          -  Renal failure as described by the pediatric RIFLE criteria

          -  H/o intracranial hemorrhage

          -  Prematurity less than 37 weeks estimated gestational age

          -  Previously diagnosed pro-thrombotic or hemorrhagic disorder

          -  Prior ATIII supplementation

          -  Prior therapeutic anticoagulant use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund Jooste, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <results_first_submitted>April 26, 2017</results_first_submitted>
  <results_first_submitted_qc>June 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2017</results_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Five subjects enrolled but withdrew prior to randomization</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Anti-thrombin III</title>
          <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anti-thrombin III</title>
          <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Normal saline placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="19.7"/>
                    <measurement group_id="B2" value="17.2" spread="30.2"/>
                    <measurement group_id="B3" value="14.6" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in ICU)</title>
        <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at Time 5 (on arrival in ICU).</description>
        <time_frame>Time 5 (on arrival in ICU)</time_frame>
        <population>The laboratory was unable to perform this blood assay due to technical issues and no results were generated.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in ICU)</title>
          <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at Time 5 (on arrival in ICU).</description>
          <population>The laboratory was unable to perform this blood assay due to technical issues and no results were generated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the Mean and SD of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Times 5-Time 7 (ICU Arrival to Post Operative Day 4)</title>
        <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at times 5-Time 7 (ICU arrival to Post Operative Day 4)</description>
        <time_frame>ICU arrival (Time 5) to Time 7 (Post-operative Day 4)</time_frame>
        <population>The laboratory was unable to perform this blood assay due to technical difficulties and no results were generated.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Mean and SD of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Times 5-Time 7 (ICU Arrival to Post Operative Day 4)</title>
          <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at times 5-Time 7 (ICU arrival to Post Operative Day 4)</description>
          <population>The laboratory was unable to perform this blood assay due to technical difficulties and no results were generated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the Mean the ATIII (Functional Assay) of the Control and ATIII Groups at T1, T2, T3, T5, T6 and T7</title>
        <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean of the ATIII (functional assay) of the control and ATIII groups at T1, T2, T3, T5, T6 and T7 (Baseline, 30 min after study drug, 30 min on CPB, Arrival in ICU, POD 2, and POD 4). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
        <time_frame>T1, T2, T3, T5, T6 and T7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Mean the ATIII (Functional Assay) of the Control and ATIII Groups at T1, T2, T3, T5, T6 and T7</title>
          <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean of the ATIII (functional assay) of the control and ATIII groups at T1, T2, T3, T5, T6 and T7 (Baseline, 30 min after study drug, 30 min on CPB, Arrival in ICU, POD 2, and POD 4). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
          <units>% Functional Activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="12"/>
                    <measurement group_id="O2" value="54" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2 (30 minutes post study drug)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="19"/>
                    <measurement group_id="O2" value="49" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3 (30 minutes on CPB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="20"/>
                    <measurement group_id="O2" value="55" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5 (Arrival in ICU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="18"/>
                    <measurement group_id="O2" value="63" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6 (POD 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="15"/>
                    <measurement group_id="O2" value="57" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T7 (POD 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="20"/>
                    <measurement group_id="O2" value="66" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T1 (Baseline)</non_inferiority_desc>
            <p_value>0.982</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T2 (30 minutes after study drug)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T3 (30 minutes on CPB)</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T5 (Arrival in ICU)</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T6 (POD 2)</non_inferiority_desc>
            <p_value>0.840</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T7 (POD 4)</non_inferiority_desc>
            <p_value>0.475</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the Median of the ATIII (Functional Assay) of the Control and ATIII Groups at T4</title>
        <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the ATIII (functional assay) of the control and ATIII groups at T4 (just prior to coming off of CPB). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
        <time_frame>T4 (just prior to coming off of CPB)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Median of the ATIII (Functional Assay) of the Control and ATIII Groups at T4</title>
          <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the ATIII (functional assay) of the control and ATIII groups at T4 (just prior to coming off of CPB). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage.</description>
          <units>% Functional Activity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="69.5" upper_limit="95.0"/>
                    <measurement group_id="O2" value="69.0" lower_limit="35.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T4 (just prior to coming off of CPB)</non_inferiority_desc>
            <p_value>0.048</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the Median of the D Dimer of the Control and ATIII Groups at T1, T5, T6 and T7</title>
        <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the D dimer of the control and ATIII groups at T1 (Baseline), T5 (Arrival in Intensive Care Unit), T6 (Post-Operative Day 2) and T7 (Post-Operative Day 4).</description>
        <time_frame>T1, T5, T6 and T7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Median of the D Dimer of the Control and ATIII Groups at T1, T5, T6 and T7</title>
          <description>Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the median of the D dimer of the control and ATIII groups at T1 (Baseline), T5 (Arrival in Intensive Care Unit), T6 (Post-Operative Day 2) and T7 (Post-Operative Day 4).</description>
          <units>mcg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.7" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5 (Arrival in ICU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.5" upper_limit="0.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.6" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6 (POD 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.9" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T7 (POD 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.3" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T1 (Baseline)</non_inferiority_desc>
            <p_value>0.855</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T5 (Arrival in ICU)</non_inferiority_desc>
            <p_value>0.225</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T6 (POD 2)</non_inferiority_desc>
            <p_value>0.313</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T7 (POD 4)</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Heparin at the ICU Arrival Time Point Represented by a Decreased Anti Factor Xa Level.</title>
        <description>Evidence of a decreased amount of residual heparin at the Intensive Care Unit arrival time point (T5) represented by a decreased anti factor Xa level.</description>
        <time_frame>T5 (Intensive Care Unit Arrival)</time_frame>
        <population>In both arms, heparin level was undetectable as Anti factor Xa level was less than or equal to 0.1 IU/ml in all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Heparin at the ICU Arrival Time Point Represented by a Decreased Anti Factor Xa Level.</title>
          <description>Evidence of a decreased amount of residual heparin at the Intensive Care Unit arrival time point (T5) represented by a decreased anti factor Xa level.</description>
          <population>In both arms, heparin level was undetectable as Anti factor Xa level was less than or equal to 0.1 IU/ml in all subjects.</population>
          <units>International Units/milliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0"/>
                    <measurement group_id="O2" value="0.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evidence of Decreased Inflammation Represented by a Decrease in Inflammatory Markers in the ATIII Group</title>
        <description>Evidence of decreased inflammation represented by a decrease in inflammatory markers in the ATIII group.</description>
        <time_frame>Baseline (T1) to Post-Operative Day 4 (T7)</time_frame>
        <population>Laboratory testing not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Evidence of Decreased Inflammation Represented by a Decrease in Inflammatory Markers in the ATIII Group</title>
          <description>Evidence of decreased inflammation represented by a decrease in inflammatory markers in the ATIII group.</description>
          <population>Laboratory testing not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Heparin While on Cardiopulmonary Bypass</title>
        <description>Total dose of Heparin while on Cardiopulmonary Bypass</description>
        <time_frame>T1 (Baseline) to T5 (Arrival in ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Heparin While on Cardiopulmonary Bypass</title>
          <description>Total dose of Heparin while on Cardiopulmonary Bypass</description>
          <units>units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3775" lower_limit="3400.0" upper_limit="5700.0"/>
                    <measurement group_id="O2" value="5000" lower_limit="4200.0" upper_limit="6300.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T1 (Baseline) to T5 (Arrival in ICU)</non_inferiority_desc>
            <p_value>0.056</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protamine Dose Determined by Hemostasis Management System Machine (mg/kg)</title>
        <description>Protamine dose determined by Hemostasis Management system machine (mg/kg)</description>
        <time_frame>T1 (Baseline) to T5 (Arrival in ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Protamine Dose Determined by Hemostasis Management System Machine (mg/kg)</title>
          <description>Protamine dose determined by Hemostasis Management system machine (mg/kg)</description>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="9.1" upper_limit="10.1"/>
                    <measurement group_id="O2" value="10.0" lower_limit="6.5" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>T1 (Baseline) to T5 (Arrival in ICU)</non_inferiority_desc>
            <p_value>0.545</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Blood Products While on CPB</title>
        <description>Total volume of blood products exposed intraoperatively including the pump prime (ml/kg)</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Blood Products While on CPB</title>
          <description>Total volume of blood products exposed intraoperatively including the pump prime (ml/kg)</description>
          <units>mls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Volume Red Blood Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="103.9"/>
                    <measurement group_id="O2" value="101.5" spread="128.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Volume Fresh Frozen Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="121.5"/>
                    <measurement group_id="O2" value="141.9" spread="133.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total volume ultrafiltration Platelet transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" spread="44.2"/>
                    <measurement group_id="O2" value="72.6" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total volume Cryoprecipitate transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="22.8"/>
                    <measurement group_id="O2" value="33.8" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Protamine Administration to Skin Dressing</title>
        <description>Time from protamine administration to skin dressing</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Protamine Administration to Skin Dressing</title>
          <description>Time from protamine administration to skin dressing</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" lower_limit="65.0" upper_limit="123.0"/>
                    <measurement group_id="O2" value="89.0" lower_limit="60.0" upper_limit="155.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</non_inferiority_desc>
            <p_value>0.757</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Fresh Frozen Plasma Given Prior to CPB</title>
        <description>Total volume of Fresh Frozen Plasma given prior to CPB, including the pump prime (ml/kg)</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Fresh Frozen Plasma Given Prior to CPB</title>
          <description>Total volume of Fresh Frozen Plasma given prior to CPB, including the pump prime (ml/kg)</description>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="67.1"/>
                    <measurement group_id="O2" value="5.8" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</title>
        <description>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</description>
        <time_frame>Baseline (Intraoperatively)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</title>
          <description>Incidence of Recombinant Factor 7a (VIIa) Use Intraoperatively</description>
          <units>count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Postoperative Blood Loss</title>
        <description>Volume of postoperative blood loss from 10min post protamine administration to 24 hour post protamine administration- (ml/kg)</description>
        <time_frame>From 10min post protamine administration to 24 hour post protamine administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Postoperative Blood Loss</title>
          <description>Volume of postoperative blood loss from 10min post protamine administration to 24 hour post protamine administration- (ml/kg)</description>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hour postop Fresh Frozen Plasma exposures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.4"/>
                    <measurement group_id="O2" value="2.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour postop Platelet exposures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="2.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour postop Cryoprecipitate exposures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="2.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour postop Red Blood Cell exposures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="7.3"/>
                    <measurement group_id="O2" value="10.1" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2741</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hour postop Fresh Frozen Plasma exposures</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0351</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hour postop Platelet exposures</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hour postop Cryoprecipitate exposures</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0196</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hour postop Red Blood Cell exposures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest Tube Output (Protamine Time Plus 24 Hours) in Milliliters</title>
        <description>Chest Tube output (protamine time plus 24 hours) in milliliters</description>
        <time_frame>protamine time plus 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Chest Tube Output (Protamine Time Plus 24 Hours) in Milliliters</title>
          <description>Chest Tube output (protamine time plus 24 hours) in milliliters</description>
          <units>milliters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="46.5" upper_limit="83.5"/>
                    <measurement group_id="O2" value="113.0" lower_limit="67.0" upper_limit="210.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>protamine time plus 24 hours</non_inferiority_desc>
            <p_value>0.016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Blood Product Units Transfused by Type 24-hours Post-operatively by Group</title>
        <description>Number of packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
        <time_frame>24 Hours Post-Operatively</time_frame>
        <population>Unable to be calculated accurately as blood products given in CPB prime were only designated in Units administered and not mls (no record of how many mls present in each unit). Therefore unable to back calculate total mls given from start of surgery to 24 hours postop</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Blood Product Units Transfused by Type 24-hours Post-operatively by Group</title>
          <description>Number of packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
          <population>Unable to be calculated accurately as blood products given in CPB prime were only designated in Units administered and not mls (no record of how many mls present in each unit). Therefore unable to back calculate total mls given from start of surgery to 24 hours postop</population>
          <units>Units</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fresh Frozen Plasma Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryo-Precipitate Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Blood Product Units Transfused 24-hours Post-operatively by Group</title>
        <description>Number of total blood product units (including packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units) transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
        <time_frame>24 Hours Post-Operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Blood Product Units Transfused 24-hours Post-operatively by Group</title>
          <description>Number of total blood product units (including packed Fresh frozen plasma units, Platelet Units, cryo-precipitate units, and Red Blood Cell units) transfused 24 hours post-operatively for each group (not total units transfused for each subject)</description>
          <units>Units</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>24 Hours Post-Operatively</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Recombinant Factor 7a (VIIa) Used Intraoperatively</title>
        <description>Total Dose of rescue recombinant factor 7a (VIIa) used intraoperatively</description>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Recombinant Factor 7a (VIIa) Used Intraoperatively</title>
          <description>Total Dose of rescue recombinant factor 7a (VIIa) used intraoperatively</description>
          <units>mcg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="118.2"/>
                    <measurement group_id="O2" value="70.6" spread="174.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.927</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Post Operative Ventilation in Days</title>
        <description>Length of post operative ventilation in days</description>
        <time_frame>ICU arrival (Time 5) to Time 7 (Post-Operative Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Post Operative Ventilation in Days</title>
          <description>Length of post operative ventilation in days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2"/>
                    <measurement group_id="O2" value="3.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Extracorporeal Membrane Oxygenation (ECMO) Support Within 24 Hours Postoperatively</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the incidence of extracorporeal membrane oxygenation (ECMO) support within 24 hours postoperatively.</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Extracorporeal Membrane Oxygenation (ECMO) Support Within 24 Hours Postoperatively</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the incidence of extracorporeal membrane oxygenation (ECMO) support within 24 hours postoperatively.</description>
          <units>number</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.231</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Mediastinal Exploration Within 24 Hours Postoperatively</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the incidence of mediastinal exploration within 24 hours postoperatively</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Mediastinal Exploration Within 24 Hours Postoperatively</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the incidence of mediastinal exploration within 24 hours postoperatively</description>
          <units>count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence (Number) of Thrombotic Events Documented</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of thrombotic events documented.</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence (Number) of Thrombotic Events Documented</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of thrombotic events documented.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Onset Renal Failure, Defined by Stage 3 of the AKIN Criteria</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the incidence of new onset renal failure, defined by stage 3 of the Acute Kidney Injury Network (AKIN) criteria.
Serum creatinine increase ≥26.5 μmol/l (≥0.3 mg/dl) or increase to 1.5–2.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 6 hours
Serum creatinine increase &gt;2.0–3.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 12 hours
Serum creatinine increase &gt;3.0-fold from baseline or serum creatinine ≥354 μmol/l (≥4.0 mg/dl) with an acute increase of at least 44 μmol/l (0.5 mg/dl) or need for Renal replacement therapy (RRT), urine output &lt;0.3 ml/kg/h for 24 h or anuria for 12 hours or need for RRT</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Onset Renal Failure, Defined by Stage 3 of the AKIN Criteria</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the incidence of new onset renal failure, defined by stage 3 of the Acute Kidney Injury Network (AKIN) criteria.
Serum creatinine increase ≥26.5 μmol/l (≥0.3 mg/dl) or increase to 1.5–2.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 6 hours
Serum creatinine increase &gt;2.0–3.0-fold from baseline, urine output &lt;0.5 ml/kg/h for 12 hours
Serum creatinine increase &gt;3.0-fold from baseline or serum creatinine ≥354 μmol/l (≥4.0 mg/dl) with an acute increase of at least 44 μmol/l (0.5 mg/dl) or need for Renal replacement therapy (RRT), urine output &lt;0.3 ml/kg/h for 24 h or anuria for 12 hours or need for RRT</description>
          <units>count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence (Number) of Newly Diagnosed Intracranial Hemorrhage</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of newly diagnosed intracranial hemorrhage</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence (Number) of Newly Diagnosed Intracranial Hemorrhage</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the incidence (number) of newly diagnosed intracranial hemorrhage</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Time to Delayed Sternal Closure Measured in Days</title>
        <description>Study the safety profile of dosing the ATIII by monitoring the length of time to delayed sternal closure measured in days</description>
        <time_frame>Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-thrombin III</title>
            <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Time to Delayed Sternal Closure Measured in Days</title>
          <description>Study the safety profile of dosing the ATIII by monitoring the length of time to delayed sternal closure measured in days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.1"/>
                    <measurement group_id="O2" value="2.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Baseline (intraoperatively) until post-operative day four.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anti-thrombin III</title>
          <description>Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
* expressed as a % normal level based on functional ATIII assay</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension R/T bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intraop Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension R/T chest fluid retention (not bleeding)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Right-sided tonic clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Right-sided subdural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ECMO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Low Hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Desaturation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intermittent PVCs R/T Low K, Low Mg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemoparitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Junctional ectopic tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Junctional rhythm tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>SVTs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Echogenic focus in occipital parietal region</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Posterior subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Right Lung Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edmund Jooste</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-4877</phone>
      <email>edmund.jooste@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

